Phase I Study of BC-819/PEI and BCG in Patients With Superficial Transitional Cell Bladder Carcinoma.
Phase of Trial: Phase I
Latest Information Update: 27 Feb 2017
At a glance
- Drugs BC 819 (Primary) ; BC 819 (Primary) ; BCG; BCG
- Indications Bladder cancer
- Focus Adverse reactions
- Sponsors BioCancell Therapeutics
- 01 Oct 2015 Results published in BioCancell media release.
- 25 Mar 2014 According to ClinicalTrials.gov record study design changed from randomized to non-randomized; number of patients increased from 12 to 18; and an additional arm group (BC-819 + BCG ) is added.
- 25 Mar 2014 Planned number of patients changed from 12 to 18 as per ClinicalTrials.gov record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History